Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trialAndrew R. Clamp, Jonathan A. Ledermann, Sarah P. Blagden et al.|The Lancet|2019Cited by 223
ICON8: A GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression- free survival (PFS) analysisA. Clamp, Jonathan A. Ledermann, Iain A. McNeish et al.|Annals of Oncology|2017Cited by 51
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trialAndrew R. Clamp, Jonathan A. Ledermann, Elizabeth C James et al.|The Lancet Oncology|2022Cited by 45
805O ICON8: Overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatmentAndrew R. Clamp, Jonathan A. Ledermann, Elizabeth C James et al.|Annals of Oncology|2020Cited by 4